

September 3, 2014

## **Creoptix AG announces carbonic anhydrase data highlighting the exceptional high resolution of the Creoptix™ WAVE system.**

Creoptix AG proudly announces carbonic anhydrase data demonstrating the exceptional high sensitivity and resolution of the recently launched Creoptix™ WAVE system for the label-free analysis of molecular interactions.

The carbonic anhydrase system is an established known reference system in the field of label-free molecular interactions and therefore allows optimal benchmarking. The compelling data have led to Creoptix' first application note to be published as "Small Molecule Kinetics". The application note can be downloaded from the Company's website.

"These data demonstrate the outstanding sensitivity of our WAVE-system. Especially the high resolution observed with methysulfonamide is exceptional," said Dr. Kaspar Cottier, CTO and founder of Creoptix AG. "With the WAVE-system, we provide a solution for today's increasingly demanding applications in the drug discovery industry, like fragment-based screening or characterization of weak interactions."

Creoptix™ WAVE is designed for all kind of label-free interaction measurements, such as for generating kinetic, affinity, specificity or concentration data. Due to its performance and high resolution at even low signal levels it is especially addressing applications with a need for high sensitivity, such as analyzing very small molecules like in fragment based drug screening, or when low concentrations are required to save precious reagents or to avoid avidity effects in antibody studies.

To request further information about Creoptix™ WAVE, please feel free to contact us by e-mail at [info@creoptix.com](mailto:info@creoptix.com) or phone: +41 44 533 26 60.

### About Creoptix AG

Creoptix AG is a privately-held company focused on the development of next generation instruments for the high-sensitivity analysis of label-free molecular interactions based on an innovative, proprietary technology.

Creoptix' instruments are characterized by very high sensitivity while still being robust and customer-friendly. The main applications for its instruments are in the drug discovery industry and for life-science and materials research.

Creoptix was founded in 2009.

Creoptix AG, Einsiedlerstrasse 34, 8820 Wädenswil, Switzerland